Autologous immunotherapy for human leukemias

David Claxton, Shing Fen Kao

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Immunotherapy for human leukemias has the potential to contribute to the long-term control or cure of these diseases. Our work demonstrates that cells from the majority of adult acute myelogenous leukemia cases can be induced to differentiate into dendritic cells that are effective at antigen presentation. Both interleukin-4 and CD40 ligand are important for optimal dendritic cell differentiation and maturation. Granulocyte-monocyte colony-stimulating factor, interleukin-4, and CD40 ligand in combination are capable of yielding dendritic cells from at least some cases of acute lymphocytic leukemia. Efforts to clone autologous, cytotoxic effector cells will permit the identification of target antigens in the future. With information concerning potential antigens, protocols inducing antileukemic immunity should be possible. Prior to that time, with the availability of suitable reagents for clinical scale differentiation of leukemia-derived dendritic cells, such cells might prove potent as vaccines for the therapy of acute leukemias.

Original languageEnglish (US)
Pages (from-to)121-124
Number of pages4
JournalBlood Cells, Molecules, and Diseases
Issue number1
StatePublished - 2003

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Autologous immunotherapy for human leukemias'. Together they form a unique fingerprint.

Cite this